How Bad Is Kidney Cancer: Stages, Survival, and Spread

Kidney cancer ranges from one of the most curable solid tumors to one of the most lethal, and the difference comes down almost entirely to when it is caught. A small tumor confined to the kidney can often be removed with surgery and carries a five-year survival rate well above 90 percent. Once the disease has spread to distant organs, that number drops dramatically, with median overall survival measured in months rather than years for high-grade tumors. Roughly 435,000 new cases are diagnosed worldwide each year, and the global burden is projected to rise sharply by 2050.

Why Stage at Diagnosis Changes Everything

Kidney cancer staging follows the familiar TNM system, where T describes the size and local extent of the primary tumor, N describes whether nearby lymph nodes are involved, and M indicates distant spread. For the reader trying to understand a diagnosis, here is the practical meaning of each stage:

Stage I: The tumor is 7 cm or smaller and entirely within the kidney. This is the most favorable scenario, and partial removal of the kidney is often enough.
Stage II: The tumor is larger than 7 cm but still confined to the kidney. Surgery remains the standard treatment, though the entire kidney is more likely to be removed.
Stage III: The cancer has grown into major veins near the kidney, into the surrounding fat, or has reached one or more nearby lymph nodes. Lymph node involvement roughly doubles the risk of the cancer eventually appearing in distant organs and pulls five-year survival down considerably, with estimates ranging from about 5 to 38 percent depending on the extent of nodal disease.¹
Stage IV: The tumor has spread beyond the kidney’s local region to distant organs like the lungs, bones, liver, or brain. This is where kidney cancer earns its reputation as a difficult disease.

The steep drop in outcomes between localized and metastatic disease is one of the sharpest in oncology. Patients without lymph node involvement have an estimated five-year survival above 50 percent, while those with positive nodes face a dramatically reduced outlook.¹ That gap is why so much emphasis falls on catching the disease before it escapes the kidney.

Where Kidney Cancer Tends to Spread

Kidney cancer has a well-known affinity for certain organs when it metastasizes. An analysis of the SEER database found that among patients with distant metastases, about 55 percent had lung involvement, roughly 38 percent had bone metastases, about 20 percent had liver metastases, and around 10 percent had brain involvement.² Many patients had cancer in more than one of these sites simultaneously. The specific pattern of spread matters for prognosis: lung metastases, for example, were identified as an independent predictor of worse outcomes in one multicenter study of metastatic non-clear cell kidney cancer.³

One particularly striking behavior of kidney cancer is its tendency to grow into blood vessels. Up to about 10 percent of patients have tumor thrombus extending into the inferior vena cava at diagnosis, and nearly a third of those patients also have concurrent metastatic disease.⁴ Surgery to remove both the kidney and the tumor thrombus from the vein is complex, but it remains the only way to achieve local control and can produce durable results in roughly half of these patients.⁴

Most Kidney Cancers Are Found by Accident

Unlike many cancers, kidney cancer rarely announces itself early. There is no widely recommended screening test for the general population, and the classic symptoms people associate with it, such as blood in the urine, flank pain, and a palpable mass, usually appear only after the tumor has grown substantially. The result is that close to half of all renal cell carcinomas today are discovered incidentally, typically when someone gets an abdominal CT or ultrasound for an unrelated reason.⁵

This incidental detection trend has actually been a mixed blessing. On one hand, it catches many small, treatable tumors that would otherwise go unnoticed until they were more advanced. On the other hand, it has contributed to a steady rise in incidence rates over the past several decades: the rate of kidney cancer in the United States has more than doubled in the last 50 years, driven in part by the growing use of cross-sectional imaging.⁵ That rise in detection has not been matched by a proportional rise in deaths, suggesting that many of the tumors being found early are less aggressive. Still, differentiating an indolent small mass from one that will eventually become dangerous remains a real clinical challenge. One study of incidental renal masses found on CT showed that about 87 percent of the masses could be classified as benign, while roughly 13 percent were indeterminate and required further evaluation.⁶

Not All Kidney Cancers Behave the Same

The umbrella term “kidney cancer” covers several distinct diseases, and the subtype matters for both prognosis and treatment selection. Clear cell renal cell carcinoma is by far the most common, accounting for roughly 70 to 80 percent of cases. It is also the most studied, meaning that most survival statistics and treatment trials apply primarily to this subtype.

Papillary renal cell carcinoma is the second most common and comes in two flavors. Type 1 papillary tumors tend to be slow-growing and carry a notably better prognosis than clear cell cancer when the disease has not spread. One large study found that type 1 papillary tumors had a risk of cancer-specific death reduced by about 69 percent compared to clear cell tumors in non-metastatic settings.⁷ Type 2 papillary tumors, however, behave much more aggressively and show survival outcomes that are essentially equivalent to clear cell cancer.⁷ Other subtypes include chromophobe renal cell carcinoma, which generally has a favorable outlook, and collecting duct carcinoma, which is rare and tends to be very aggressive.

Beyond subtype, the tumor’s grade under the microscope provides important information. The current standard is the ISUP grading classification, which rates tumors on a scale from 1 to 4 based on how abnormal the cells look, with grades 1 through 3 defined by how prominent the nucleoli are and grade 4 reserved for tumors showing bizarre giant cells or sarcomatoid features.⁸ In metastatic disease, the grade has a meaningful effect on survival: one multi-institutional study found median overall survival of about 28 months for low-grade metastatic tumors versus 16 months for high-grade tumors.⁹ The presence of a sarcomatoid component was an independent predictor of worse outcomes.⁹

Risk Factors That Increase Your Chances

Several modifiable risk factors have been convincingly linked to kidney cancer. A systematic review that compiled results across dozens of studies found that obesity and hypertension were harmful in virtually every study examined: all 36 studies on obesity and 17 of 18 studies on hypertension showed an increased risk.¹⁰ Smoking was detrimental in 13 of 14 studies, and diabetes added risk in 23 of 27 studies.¹⁰ Physical activity, by contrast, appeared protective in the majority of studies reviewed.

The obesity connection is particularly strong. In a large cohort of men, those in the highest weight categories had nearly double the risk of renal cell cancer compared to those in the lowest categories. Higher blood pressure levels independently added risk beyond what weight alone could explain.¹¹ Importantly, the relationship between blood pressure and kidney cancer held even after excluding the first five years of follow-up, which helped rule out the possibility that undiagnosed cancer was causing the high blood pressure rather than the other way around.¹¹ A separate study of two large cohorts confirmed that the association between blood pressure and kidney cancer held independently in both men and women, regardless of body weight or smoking status.¹²

One surprising finding in the systematic review: moderate alcohol consumption appeared to be protective in the majority of studies, a pattern that runs counter to what is seen with many other cancer types.¹⁰ The mechanism behind this association is not well understood, and it should not be taken as a reason to drink. The dietary evidence overall was mixed, with roughly equal numbers of studies finding benefit, harm, or no effect from various dietary patterns.

Surgery and the Cost to Your Kidneys

For localized kidney cancer, surgery remains the primary treatment. The two main options are partial nephrectomy, which removes only the tumor and a margin of normal tissue, and radical nephrectomy, which removes the entire kidney. The choice between them depends on tumor size, location, and the patient’s overall health, but the trend in recent years has been strongly toward kidney-sparing approaches whenever feasible.

The reason for that trend goes beyond cancer control. Among older patients with early-stage disease, those treated with partial nephrectomy had a substantially lower risk of death than those who had the entire kidney removed. One study estimated that treating just 7 patients with partial rather than radical nephrectomy would prevent 1 death over 8 years of follow-up.¹³ The cancer-specific survival between the two approaches showed no significant difference, suggesting that the survival advantage of partial nephrectomy comes from preserving kidney function and reducing cardiovascular and metabolic consequences of losing an entire kidney.¹³ A separate study found that partial nephrectomy was associated with lower all-cause mortality in the first five years after surgery compared to radical nephrectomy.¹⁴

Kidney function decline after surgery is a real concern. Factors associated with declining kidney function include having a radical rather than partial nephrectomy, older age, higher body weight, and pre-existing cardiovascular problems.¹⁵ The risk of eventually needing dialysis is relatively small overall but rises steeply with pre-existing kidney disease. One study found that the five-year cumulative incidence of end-stage kidney disease following a kidney cancer diagnosis was about 2.4 percent, compared to 0.4 percent in matched controls without cancer.¹⁶ Patients who did develop end-stage kidney disease had significantly worse survival, underscoring why nephron-sparing surgery and active surveillance of small tumors in elderly or comorbid patients are increasingly favored strategies.¹⁶

For older patients with significant health problems and a small renal mass, active surveillance, meaning regular imaging without immediate treatment, has gained acceptance. Evidence supports the safety of this approach in patients who face high surgical risk, with satisfactory intermediate-term outcomes.¹⁷ Focal ablation, which destroys the tumor with heat or cold through a needle rather than cutting it out, is another option in this population.

How Treatment Has Changed for Advanced Disease

The treatment of metastatic kidney cancer has been transformed over the past decade by immunotherapy. Until recently, the standard first-line treatment was a single targeted drug like sunitinib, which blocks the blood vessel growth that kidney tumors depend on. Those drugs could slow the disease but rarely produced the kind of deep, lasting responses patients needed. Checkpoint inhibitors changed the picture substantially.

In the second-line setting, the checkpoint inhibitor nivolumab showed an overall survival benefit over the previous standard, with about 26 percent of patients still alive at five years compared to 18 percent with the older drug.¹⁸ Long-term durable responses were reported in a meaningful fraction of patients who initially responded.¹⁸ The combination of two checkpoint inhibitors, ipilimumab and nivolumab, showed unprecedented efficacy as a first-line treatment compared to sunitinib, meeting all of its primary endpoints in intermediate- and poor-risk patients.

Today, several combinations of checkpoint inhibitors with targeted drugs are used as frontline therapy. A network meta-analysis found that all tested combinations outperformed sunitinib alone for overall survival, with pembrolizumab plus axitinib and nivolumab plus cabozantinib ranking highest in probability analyses.¹⁹ When patients progress on immunotherapy-based regimens, drugs targeting vascular growth factors still have meaningful activity as a later line of treatment, with median overall survival ranging from 11 to 30 months depending on the specific regimen and setting.²⁰

Risk stratification plays a central role in treatment decisions for advanced kidney cancer. The IMDC criteria, which incorporate factors like time from diagnosis to treatment, performance status, and blood test results, divide patients into favorable, intermediate, and poor risk groups. The difference between these groups is dramatic: one study found that the hazard ratio for death in poor-risk patients was nearly nine times that of favorable-risk patients.³ These models have limitations: they rely on clinical and pathologic variables alone and do not yet incorporate molecular or genomic data in routine practice.²¹

Recurrence After Seemingly Successful Surgery

Even when kidney cancer is caught early and surgically removed, the disease can come back. Estimates suggest that between 20 and 40 percent of patients treated with nephrectomy for clinically localized disease will experience a recurrence.²² Recurrence can appear months or even many years after surgery, which is one of kidney cancer’s distinctive and frustrating features. Late recurrences a decade or more after the initial surgery, while uncommon, are well documented. This extended window of risk is why surveillance after surgery typically continues for years, with periodic imaging to catch any return of the disease when it may still be manageable.

The risk of recurrence depends heavily on the original tumor’s stage and grade. A small, low-grade stage I tumor carries a much lower recurrence risk than a large, high-grade stage III tumor. Ongoing research is attempting to identify molecular markers that can better predict which patients are at highest risk, allowing doctors to tailor the intensity of follow-up surveillance accordingly.

When Kidney Cancer Runs in the Family

Most kidney cancer is sporadic, meaning it arises from a combination of environmental exposures, aging, and random genetic events. But a meaningful minority of cases are linked to inherited genetic syndromes. The most well-known of these is von Hippel-Lindau disease, caused by mutations in the VHL gene, which predisposes people to clear cell renal cell carcinoma along with tumors in other organs. In one study of patients with hereditary kidney tumor syndromes, tuberous sclerosis complex was the most common diagnosis, followed by VHL disease and Birt-Hogg-Dubé syndrome.²³

Hereditary kidney cancers tend to appear at younger ages, are often bilateral or multifocal, and may require a different management strategy than sporadic cases. In VHL patients, the complexity of the genetic picture matters: patients carrying co-mutations alongside their VHL mutation had significantly higher rates of developing kidney cancer (about 80 percent versus 58 percent) and their tumors grew faster on imaging.²⁴ A family history of kidney cancer, especially with early onset or bilateral tumors, is a strong signal to discuss genetic testing with a specialist.

Paraneoplastic Syndromes and Unusual Presentations

Kidney cancer has long been called “the internist’s tumor” because of its tendency to produce symptoms that seem to have nothing to do with the kidneys. Close to a third of patients show signs of a paraneoplastic syndrome, meaning the cancer produces substances that affect distant parts of the body.²⁵ These can range from constitutional symptoms like unexplained fevers, weight loss, and fatigue to specific biochemical problems like high calcium levels or abnormal liver function tests even when the cancer has not spread to the liver. The variety of these presentations means kidney cancer can masquerade as many other conditions, sometimes delaying diagnosis. Clinicians who see unexplained fevers with elevated calcium or abnormal liver enzymes in a patient without obvious liver disease will often check for a kidney mass. In some patients, the paraneoplastic symptoms resolve completely after the tumor is removed, which can serve as a useful indicator that the surgery was successful and as a potential early warning system if the symptoms return.

The Rising Global Burden

Kidney cancer is not a rare disease, and it is becoming less rare over time. Globally, incidence rose from about 160,000 cases in 1990 to roughly 390,000 in 2021.²⁶ In 2022, about 435,000 new cases and 156,000 deaths were recorded.²⁷ Projections estimate roughly 746,000 new cases and 305,000 deaths by 2050, representing a 72 percent increase in incidence and a 96 percent increase in mortality.²⁷

The burden falls unevenly. Countries with higher socioeconomic development indices tend to have higher rates of kidney cancer, likely reflecting both greater exposure to risk factors like obesity and greater access to imaging that detects more cases.²⁶ China had the most cases and deaths in absolute terms in 2021, followed by the United States.²⁶ On a brighter note, 49 countries, mostly in Western Europe and North America, have seen a decreasing trend in age-standardized mortality rates over recent decades, suggesting that earlier detection and improved treatment are making a measurable difference in wealthier health systems even as overall case counts rise.

1
PubMed Central. Assessing lymph node status in patients with kidney cancer
2
Scientific Reports. The prognosis and clinicopathological features of different distant metastases patterns in renal cell carcinoma: analysis based on the SEER database
3
PubMed. Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium
4
PubMed Central. Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma
5
PubMed Central. Ultrasound in Renal Cancer Screening: A Review of the Literature
6
PubMed. Incidental finding of renal masses at unenhanced CT: prevalence and analysis of features for guiding management
7
PLOS ONE. Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease
8
PubMed Central. The ISUP system of staging, grading and classification of renal cell neoplasia
9
Scientific Reports. Survival pattern of metastatic renal cell carcinoma patients according to WHO/ISUP grade: a long-term multi-institutional study
10
PubMed. Systematic review of modifiable risk factors for kidney cancer
11
PubMed. Obesity, hypertension, and the risk of kidney cancer in men
12
PubMed Central. Hypertension and Obesity and the Risk of Kidney Cancer in Two Large Cohorts of US Men and Women
13
JAMA. Long-term Survival Following Partial vs Radical Nephrectomy Among Older Patients With Early-Stage Kidney Cancer
14
PubMed Central. Partial vs. radical nephrectomy and the risk of all-cause mortality, cardiovascular, and nephrological outcomes
15
PubMed Central. Predictors of long-term renal function after kidney surgery for patients with preoperative chronic kidney disease
16
Scandinavian Journal of Urology. End-stage renal disease after renal cancer surgery: risk factors and overall survival
17
PubMed Central. Active surveillance and focal ablation for small renal masses: a better solution for comorbid patients
18
European Urology Open Science. Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not
19
PubMed Central. Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis
20
Cancer Treatment Reviews. Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review
21
PubMed Central. Risk Stratification in Renal Cell Carcinoma: A Narrative Review
22
PubMed Central. Surveillance strategies for renal cell carcinoma patients following nephrectomy
23
PubMed Central. Hereditary kidney tumor syndromes: structured evaluation of a questionnaire-based approach
24
PubMed Central. Comparison of clinical characteristics between patients with single mutation and co-mutation in hereditary renal cancer: a retrospective analysis of 115 patients with von Hippel-Lindau syndrome
25
PubMed Central. Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma
26
PubMed Central. Global and regional burden of kidney cancer from 1990 to 2021: analysis and future predictions based on global burden of disease study
27
European Urology. Epidemiology of Renal Cancer: Incidence, Mortality, Survival, Genetic Predisposition, and Risk Factors